Replacement of protease inhibitors by nevirapine or efavirenz in simplification and rescue interventions: Which works better?

HIV Clinical Trials

Volumn 4, Issue 4, 2003, Pages 244-247

  Barreiro, Pablo ^a   Camino, Nuria ^a   de Julián, Rosa ^a   González Lahoz, Juan ^a   Soriano, Vincent ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Antiretroviral therapy; Efavirenz; HIV; Nevirapine; Salvage therapy; Simplification

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; NEVIRAPINE; OXAZINE DERIVATIVE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; COMPARATIVE STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG RESISTANCE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NEUROTOXICITY; PANCREATITIS; PHYSIOLOGY; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; SALVAGE THERAPY; TIME; TREATMENT FAILURE; TREATMENT OUTCOME; VIREMIA; VIROLOGY;

ADULT; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; NEVIRAPINE; OXAZINES; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; SALVAGE THERAPY; TIME FACTORS; TREATMENT OUTCOME;

EID: 0041564055     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/G67J-C2NC-2XRD-TTMM     Document Type: Article

References (13)

1. Van Leeuwen R. The Atlantic study: a randomized, open-label trial comparing two PI-sparing antiretroviral strategies versus a standard PI-containing regimen, 2 year follow-up data. In: Program and abstracts of the 14th International AIDS Conference; July 7-12, 2002; Barcelona. Abstract MoPeB3089.
2. Staszewski S, Morales-Ramirez J, Tashima K, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med. 1999;341:1865-1873.
3. King R, Klabe R, Reid C, Erickson-Viitanen S. Potency of nonnucleoside reverse transcriptase inhibitors (NNRTIs) used in combination with other HIV NNRTIs, NRTIs, or protease inhibitors. Antimicrob Agents Chemother. 2002;46:1640-1646.
4. Deeks S, Hecht F, Swanson M, et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS. 1999;13:F35-43.
5. Barreiro P, García-Benayas T, Gallant J. The simplification strategy: sustaining success, reducing toxicity and ensuring adherence after PI therapy. AIDS Rev. 2002;4:233-241.
6. Fisac C, Fumero E, Crespo M, et al. Metabolic and body composition changes in patients switching from a PI-containing regimen to ABC, EFV or NVP. Twelve-month results of a randomized study (LIPNEFA). In: Program and abstracts of the 14th International AIDS Conference; July 7-12, 2002; Barcelona. Abstract ThPeB7354.
7. Negredo E, Cruz L, Paredes R, et al. Virological, immunological, and clinical impact of switching from PI to NVP or to EFV in patients with HIV infection and long-lasting viral suppression. Clin Infect Dis. 2002;32:504-510.
8. Ren J, Milton J, Weaver K, Short S, Stuart D, Stammers D. Structural basis for the resilience of efavirenz to drug resistance mutations in HIV-1 reverse transcriptase. Structure. 2000;8:1089-1094.
9. Cozzi-Lepri A, Phillips A, d'Arminio A, et al. Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian cohort of naive to antiretrovirals (I.Co.N.A.) study. J Infect Dis. 2002;185:1062-1069.
10. Masquelier B, Neau D, Chêne G, et al. Mechanism of virologic failure after substitution of a protease inhibitor by nevirapine in patients with suppressed plasma HIV-1 RNA. J Acquir Immune Defic Syndr. 2001;28:309-312.
11. Núñez M, Soriano V, Martín-Carbonero L, et al. SENC (Spanish Efavirenz vs Nevirapine Comparison) trial: a randomized, open-label study in HIV-infected naive individuals. HIV Clin Trials. 2002;3:186-194.
12. Sulkowski M, Thomas D, Mehta S, Chaisson R, Moore R. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy. Role of hepatitis C and B infections. Hepatology. 2002;35:182-189.
13. Treisman G, Kaplin A. Neurologic and psychiatric complications of antiretroviral agents. AIDS. 2002;16:1201-1215.